Linagliptin - Generic Drug Details

What are the generic drug sources for linagliptin and what is the scope of freedom to operate?

Linagliptin is the generic ingredient in five branded drugs marketed by Aurobindo Pharma Ltd, Dr Reddys, Invagen Pharms, MSN, Mylan, Sunshine, Zydus Pharms, and Boehringer Ingelheim, and is included in fourteen NDAs. There are sixteen patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Linagliptin has three hundred and eighty-one patent family members in forty-one countries.

There are nineteen drug master file entries for linagliptin. Four suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for linagliptin

International Patents:	381
US Patents:	16
Tradenames:	5
Applicants:	8
NDAs:	14
Drug Master File Entries:	19
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	83
Clinical Trials:	152
Patent Applications:	6,590
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for linagliptin
What excipients (inactive ingredients) are in linagliptin?	linagliptin excipients list
DailyMed Link:	linagliptin at DailyMed

Recent Clinical Trials for linagliptin

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AJU Pharm Co., Ltd.	PHASE1
Taihe Hospital	PHASE4
Wuhan Central Hospital	PHASE4

See all linagliptin clinical trials

Generic filers with tentative approvals for LINAGLIPTIN

Applicant	Application No.	Strength	Dosage Form
		2.5MG;850MG	TABLET;ORAL
		2.5MG;500MG	TABLET;ORAL
		2.5MG;1GM	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for linagliptin

Drug Class	Dipeptidyl Peptidase 4 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors

Medical Subject Heading (MeSH) Categories for linagliptin

Dipeptidyl-Peptidase IV Inhibitors

Hypoglycemic Agents

Incretins

Anatomical Therapeutic Chemical (ATC) Classes for linagliptin

A10BH	Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for LINAGLIPTIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRADJENTA	Tablets	linagliptin	5 mg	201280	11	2015-05-04

US Patents and Regulatory Information for linagliptin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	JENTADUETO XR	linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	208026-002	May 27, 2016		RX	Yes	Yes
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-001	Jan 30, 2012	AB	RX	Yes	No	8,846,695*PED				Y
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-002	Jan 30, 2012	AB	RX	Yes	No	10,022,379*PED				Y
Boehringer Ingelheim	JENTADUETO	linagliptin; metformin hydrochloride	TABLET;ORAL	201281-003	Jan 30, 2012	AB	RX	Yes	Yes	11,911,388

Expired US Patents for linagliptin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280-001	May 2, 2011	6,303,661
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280-001	May 2, 2011	8,178,541
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280-001	May 2, 2011	6,890,898
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280-001	May 2, 2011	8,119,648

EU/EMA Drug Approvals for linagliptin

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Boehringer Ingelheim International GmbH	Trajenta	linagliptin	EMEA/H/C/002110Trajenta is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults:as monotherapyin patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.as combination therapyin combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.	Authorised	no	no	no	2011-08-23

International Patents for linagliptin

Country	Patent Number	Title	Estimated Expiration
Singapore	171649	DPP IV INHIBITOR FORMULATIONS
Spain	2538818
Japan	2018193408
New Zealand	590787	DPP-4 inhibitors for treating diabetes in patients showing contraindication against metformin therapy

Supplementary Protection Certificates for linagliptin

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1532149	92128	Luxembourg		PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3, 7-DIHYDROPURIN-2, 6-DION, LES ENANTIOMERES ET LEURS SELS, EN PARTICULIER LA LINAGLIPTINE COMBINEE AVEC DU CHLORHYDRATE DE METFORMINE. LINAGLIPTINE
2187879	20/2017	Austria		PRODUCT NAME: KOMBINATION VON EMPAGLIFLOZIN UND LINAGLIPTIN ODER PHARMAZEUTISCH VERTRETBARE SALZE; REGISTRATION NO/DATE: EU/1/16/1146 (MITTEILUNG) 20161115
1532149	C 2012 003	Romania		PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-IL)-7-BUT-2-INIL-3-METIL-1-(4-METILCHINAZOLIN-2-ILMETIL)3,7-DIHIDROPURIN-2,6-DIONA, ENANTIOMERII SI SARURILE LOR IN SPECIAL LINAGLIPTIN - LINAGLIPTIN, ENANTIOMERIISI SARURILE ACCEPTABILE FARMACEUTIC; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/707/001 - RO EU/1/11/707/011; DATE OF NATIONAL AUTHORISATION: 20110824; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/707/001 - EU/1/11/707/011; DATE OF FIRST AUTHORISATION IN EEA: 20110824
2187879	SPC/GB17/031	United Kingdom		PRODUCT NAME: 1-CHLORO-4-(SS-D-GLUCOPYRANOS-1-YL)-2-(4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL)-BENZENE (I.E. EMPAGLIFLOZIN) IN COMBINATION WITH 1-((4 METHYL-QUINAZOLIN-2-YL)METHYL)-3-METHYL-7-(2-BUTYN-1-YL)-8-(3-(R)-AMINO-PIPERIDIN-1-YL)-XANTHINE (I.E. LINAGLIPTIN) OR A P; REGISTERED: UK PLGB 14598/0191 (GB) 20161115; UK EU/1/16/1146/014(NI) 20161115; UK EU/1/16/1146/015(NI) 20161115; UK EU/1/16/1146/016(NI) 20161115; UK EU/1/16/1146/017(NI) 20161115; UK EU/1/16/1146/018(NI) 20161115; UK EU/1/16/1146/007(NI) 20161115; UK EU/1/16/1146/001(NI) 20161115; UK EU/1/16/1146/013(NI) 20161115; UK EU/1/16/1146/002(NI) 20161115; UK EU/1/16/1146/003(NI) 20161115; UK EU/1/16/1146/004(NI) 20161115; UK...

Market Dynamics and Financial Trajectory for Linagliptin

Last updated: February 23, 2026

Linagliptin, marketed as Tradjenta, is a dipeptidyl peptidase-4 (DPP-4) inhibitor approved for type 2 diabetes mellitus. Its unique pharmacokinetic profile and positioning within the anti-diabetic drug market influence its market dynamics and revenue projections.

Market Overview

Product Profile and Competitive Position

Linagliptin features a single-dose, once-daily administration with primarily hepatic elimination, which reduces the need for dose adjustments in patients with renal impairment. Launched in 2011 by Boehringer Ingelheim, it competes mainly with other DPP-4 inhibitors like sitagliptin, saxagliptin, and alogliptin.

Market Penetration

As of 2023, linagliptin accounts for approximately 15% of the global DPP-4 inhibitor sales, estimated at $4.2 billion (IQVIA). Its sales volume continues to grow, driven by:

• Its favorable safety profile
• The expanding global burden of type 2 diabetes
• License agreements for wider distribution in emerging markets

Market Drivers

Increasing Prevalence of Type 2 Diabetes

The International Diabetes Federation projects a global population with diabetes to reach 537 million by 2025, up from 463 million in 2019. Growth in diagnosis and treatment drives demand for oral antidiabetics, including linagliptin.

Efficacy and Safety Profile

Linagliptin's minimal risk of hypoglycemia and weight neutrality appeal to clinicians and patients. Its hepatic clearance reduces concerns in diabetic patients with renal impairment, expanding its user base.

Competitive Landscape

The DPP-4 inhibitor market is mature but fragmented. Market share shifts depend on formulary access, clinical guidelines, and comparative efficacy. Biogen and newer entrants such as velaciguat (not yet launched) pose potential competition.

Regulatory and Patent Environment

• Patent for linagliptin is valid until 2024 in the U.S. and Europe.
• Generic versions are not yet available due to remaining patent protections and regulatory exclusivity periods.

Financial Trajectory

Revenue Estimates and Growth Rates

Analysts project the global linagliptin market to grow at a compound annual growth rate (CAGR) of 5-7% over the next five years [2]. Key drivers include expanding diabetes prevalence and geographic expansion, notably in Asia-Pacific.

Year	Estimated Global Sales (USD billion)	CAGR (estimated)
2022	4.2	—
2023	4.4	5.0%
2024	4.7	6.8%
2025	5.0	6.4%

Revenue Breakdown by Geography

North America accounts for 45% of sales, Europe 20%, Asia-Pacific 25%, and other regions 10%. Growth in Asia is rapid, driven by increasing healthcare access and diabetes awareness.

Impacts of Patent Expiry and Biosimilars

Patent expiration is expected in 2024, potentially allowing biosimilar competitors or generics to capture market share. Pricing pressures could lead to reduced per-unit revenues but may also expand overall sales volume.

R&D and Pipeline Influence

Boerhinger Ingelheim's pipeline includes next-generation DPP-4 inhibitors and fixed-dose combinations, which could extend the product's life cycle and maintain its market relevance.

Risks and Challenges

• Emergence of new drug classes (SGLT2 inhibitors, GLP-1 receptor agonists)
• Regulatory hurdles in emerging markets
• Patent challenges or legal disputes
• Pricing regulations impacting reimbursements

Market Outlook Summary

Linagliptin is positioned as a key player within oral antidiabetics. Anticipated steady growth is expected until patent expiry around 2024, after which market share and revenues could decline unless the company introduces new formulations or expanded indications.

Key Takeaways

• Linagliptin's global sales are projected to grow at a 5-7% CAGR until patent expiry in 2024.
• Its unique pharmacokinetic profile gives it a competitive advantage in renal impairment.
• Patent expiration is a key risk, potentially opening the market to biosimilars and generics.
• Growth in emerging markets and the broader diabetes epidemic sustain long-term demand.
• Competition from newer drug classes could impact market share.

FAQs

1. How does linagliptin compare to other DPP-4 inhibitors in market share?
It holds approximately 15% of global DPP-4 inhibitor sales, trailing behind sitagliptin but ahead of saxagliptin and alogliptin.

2. What are the key factors affecting linagliptin's sales post-2024?
Patent expiration, emergence of biosimilars, price reductions, and competition from newer drug classes like SGLT2 inhibitors.

3. Are there opportunities for off-label uses or additional indications?
Current approvals are limited to type 2 diabetes. Research into potential benefits for other conditions, such as cardiovascular diseases, is ongoing but not yet approved.

4. How significant is geographic expansion for linagliptin’s revenue?
High, particularly in Asia-Pacific, where rising diabetes prevalence and improved healthcare access drive sales growth.

5. What strategic actions could sustain linagliptin’s market position?
Developing fixed-dose combination products, expanding into new indications, extending patent protection, or licensing agreements for emerging markets.

---

References

[1] IQVIA. (2023). Pharmaceutical Market Data.

[2] MarketWatch. (2022). Diabetes Medications Market Forecast.

[3] European Medicines Agency. (2022). Tradjenta (linagliptin) Summary of Product Characteristics.

[4] International Diabetes Federation. (2021). IDF Diabetes Atlas, 9th Edition.